Objectives: To investigate associations of the transitional zone volume (TZV) with intraprostatic chronic inflammatory infiltrate (CII) and prostate cancer (PCa) risk in patients undergoing a first random biopsy set. Materials and Methods: The study included a homogenous population of 596 patients. The volume of the prostate and TZV were separately measured. Independent associations were investigated by multivariate logistic regression analysis. Results: The median TZV was 18 ml, CII was detected in 157 cases (26.3%), and PCa was present in 292 patients (49%). TZV was the only independent clinical factor associated with CII risk (OR = 1.014). After correcting for CII (OR = 0.276; p < 0.0001), independent factors associated with PCa risk included age (OR = 1.066), prostate specific antigen (OR = 1.177), TZV (OR = 0.919), and an abnormal digital rectal exam (OR = 2.024). Conclusion: In a patient population undergoing a first random prostate biopsy set because of suspected cancer, independent associations were detected among TZV, CII, and PCa. The association between TZV and CII was direct, but the relation between TZV and PCa was inverse. The measurement of the volume of the transitional zone was a useful parameter for evaluating chronic intraprostatic inflammation and PCa risk.

Keywords:
Prostate cancer, Chronic prostate inflammation, Prostate-specific antigen, Prostate biopsy, Prostate volume, Transitional zone volume
1.
Selman SH: The McNeal prostate: a review. Urology 2011;78:1224-1228.
2.
De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, Sciarra A, Tubaro A: The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011;60:106-117.
3.
Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, Sciarra A, Montorsi F: The role of chronic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 2013; 112:432-441.
4.
Krieger JN, Nyberg L Jr, Nickel JC: NIH consensus definition and classification of prostatitis. JAMA 1999;282:263-267.
5.
De Marzo AM, Marchi VL, Epstein JI, Nelson WG: Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999;155:1985-1992.
6.
Blumenfeld W, Tucci S, Narayan P: Incidental lymphocytic prostatitis. Selective involvement with nonmalignant glands. Am J Surg Pathol 1992;16:975-981.
7.
Porcaro AB, Novella G, Molinari A, Terrin A, Minja A, De Marco V, Martignoni G, Brunelli M, Cerruto MA, Curti P, Cavalleri S, Artibani W: Prostate volume index and chronic inflammation of the prostate type IV with respect to the risk of prostate cancer. Urol Int 2015;94:270-285.
8.
Porcaro AB, Rubilotta E, Petrozziello A, Ghimenton C, Migliorini F, Zecchini Antoniolli S, La Cola V, Monaco C, Curti P, Cavalleri S, Pianon R, Artibani W: Chronic inflammation of the prostate type IV with respect to risk of prostate cancer. Arch Ital Urol Androl 2014; 86:208-211.
9.
Porcaro AB, Novella G, Cacciamani G, De Marchi D, Corsi P, De Luyk N, Bizzotto L, Processali T, Cerasuolo M, Tamanini I, Cerruto MA, Brunelli M, Siracusano S, Artibani W: Prostate volume index associates with a decreased risk of prostate cancer: results of a large cohort of patients elected to a first biopsy set. Urol Int 2017;98:22-27.
10.
Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL: The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:1228-1242.
11.
Pierorazio PM, Walsh PC, Partin AW, Epstein JI: Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 2013;111:753-760.
12.
Epstein JI, Zelefsky MJ, Sjoberg DD, nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han m, Reddy CA, Ciezki JP, Nyberg T, Klein EA: A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 2016; 69:428-435.
13.
Gerstenbluth RE, Seftel AD, Maclennan GT, Rao RN, Corty EW, Ferguson K, Resnick MI: Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol 2002;167:2267-2270.
14.
Irani J, Goujon JM, Ragni E, Peyrat L, Hubert J, Saint F, Mottet N: High-grade inflammation in prostate as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group. Urology 1999;54:467-472.
15.
Karakiewicz PI, Benayoun S, Begin LR, Duclos A, Valiquette L, McCormack M, Bénard F, Saad F, Perrotte P: Chronic inflammation is negatively associated with prostate cancer and high-grade prostatic intraepithelial neoplasia on needle biopsy. Int J Clin Pract 2007; 61:425-430.
16.
Zhang W, Sesterhenn IA, Connelly RR, Mostofi FK, Moul JW: Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for radical difference in prostate specific antigen. J Urol 2000;163:131-136.
17.
Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro-Santamaria R, Freedland SJ: Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer 2014;120:190-196.
18.
Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG: Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005;26: 1170-1181.
19.
Singh PB, Matanhelia SS, Martin FL: A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Eur J Cancer 2008;44:928-936.
20.
Hoekx L, Jeuris W, Van Marck E, Wyndaele JJ: Elevated serum prostate specific antigen (PSA) related to asymptomatic prostatic inflammation. Acta Urol Bel 1998;66:1-2.
21.
Sindhwani P, Wilson CM: Prostatis and serum prostate-specific antigen. Curr Urol Rep 2005;6:307-312.
22.
Hochreiter WW: The issue of elevated prostate cancer evaluation in men with elevated prostate-specific antigen and chronic prostatitis. Andrologia 2008;40:130-133.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.